Drug intelligence / Profile preview

EGS0500s

Development stage: Preclinical
Lead developer: Energesis Pharmaceuticals

Overview

EGS0500s is a preclinical biologic therapeutic program being developed by Energesis Pharmaceuticals for the treatment of obesity. The program is designed to target a novel, undisclosed biological pathway, referred to by the company as "new drug target 2," which is distinct from the targets addressed by the company's small molecule candidates (EGS2632 and EGS2000s). As an earlier-stage pipeline program, EGS0500s aims to leverage biological modalities to modulate metabolic processes and provide a new therapeutic approach for weight management.

Beyond the preview

Go deeper on EGS0500s.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGS0500s.

Explore the full profile